“Joe and Mark have established track records of driving scientific and clinical strategy to advance novel therapies for patients living with devastating diseases,” said Jeff Bluestone, Ph.D., Co-founder and Chief Executive Officer of Sonoma Biotherapeutics. “We look forward to leveraging their expertise as we enter the clinic with our lead Treg product candidate and continue to advance our pipeline. I’d also like to extend my gratitude to my long-time collaborator and colleague, Fred Ramsdell, for his immense contributions to Sonoma Bio. The company would not be where it is today if it were not for Fred’s seminal discoveries and dogged pursuit of Treg cell therapeutics.”
Sonoma Biotherapeutics was founded on the work of UCSF researchers Jeff Bluestone, PhD, and Qizhi Tang, PhD.